News list

The CPMA grows and strengthens

We are pleased to announce the arrival of Dr. Med. Sébastien Adamski, FMH specialist in reproductive medicine and gynecological endocrinology, who comes to reinforce our medical team.

Dr. Adamski studied medicine in Belgium at the Free University of Bruxelles. He then completed all his training in gynecology and obstetrics in Switzerland and obtained his postgraduate title of specialist in gynecology and obstetrics in September 2013.

In 2011 he joined the CHUV fertility team after obtaining his university degree in Reproductive Medicine in Paris under the direction of Professor Jean-Marie Antoine. He shared his working time between the CHUV and the Sion Hospital where he developed a fertility unit. In early 2016, he obtained the FMH post-graduate degree in advanced training in reproductive medicine and gynecological endocrinology and became a senior physician at the CHUV. He also confirmed his position as the doctor responsible for the fertility unit of Valais by becoming the sole holder of the specialty title in this canton.

Dr. Adamski shares his activity between the CPMA and his private practice in Sion. This allows him to offer couples in Valais to be locally treated for their fertility disorder while benefiting from the support of the CPMA and its Fertas laboratory, specialized in reproductive biology.

His professional and personal backgrounds make him an open-minded person, experienced and empathetic.

Chances de grossesse au CPMA

Juillet 2018

Les chances de grossesse par transfert d'embryon(s) ont fortement augmenté suite à l'entrée en vigueur de la nouvelle loi sur la procréation médicalement assistée (LPMA) en septembre 2017 et à l'utilisation de l'incubateur de nouvelle génération Embryoscope pour tous les cycles FIV et FIV-ICSI.

 

tl_files/images/2017/TauxDeGrossesse-CPMA-Avril2018.png

 

 

Les taux de réussite des traitements par insémination artificielle avec le sperme du conjoint (IAC) ou avec le sperme d'un donneur (IAD) sont également mis à jour:

tl_files/images/2017/TauxDeGrossesse-IAC-IAD-CPMA-2017.png

New Swiss law on September 1st 2017

On September 1, 2017, modifications of the Swiss Law on Medically Assisted Procreation (LPMA) were implemented. This amendment of the law was accepted by the people on June 5, 2016 with 64% of the vote.

The LPMA now allows the genetic diagnosis of embryos before transfer into the uterus.Preimplantation genetic diagnosis (PGD, or DPI in French) is reserved for couples who carry a severe genetic abnormality.The preimplantation diagnosis of aneuploidy (DPI-A), also called "preimplantation screening" (PGS), is reserved for infertile couples with a higher risk of developing embryos with a chromosome abnormality (eg history of miscarriages, woman's age over 38 years, etc.).

The alternatives to PGD are prenatal diagnosis, treatment by donation or adoption.

However, other very important changes have also been accepted and are summarized in the table below  :

Modifications Previous Law Current Law
Preimplantation diagnosis not allowed authorized
Maximum number of embryos in culture 3 12
Cryopreservation of embryos not allowed authorized

Duration of conservation (gametes,

zygotes,embryos)

5 years 10 years


These changes allow us to identify the embryos most likely to implant in the uterus and to start a pregnancy, by allowing them to evolve in the embryoscope until the 5th day of development (blastocyst stage). In most situations, only one embryo will be transferred into the uterus. This is in order to limit twin pregnancies, which are always more at risk for the babies and the mother.
The supernumerary blastocysts will be frozen by vitrification.

With this new law, the Swiss clinics that obtain the prerequisite cantonal authorizations, have access to the majority of possibilities for medically assisted procreation offered in neighboring countries (exception: oocyte donation is still prohibited in Switzerland).

The CPMA welcomes the fact that in the context of assisted reproductive technologies (ART), blastocyst transfers make it possible to shorten the duration of treatments and to reduce the costs per pregnancy obtained.

Embryoscope

The EmbryoScope +, a new technology for the benefit of embryos, will be in service at the CPMA as of September 1st, 2017.

In the area of ​​IVF, one of the greatest challenges is identifying the embryo allowing to achieve pregnancy. The EmbryoScope +, through its optimal incubation quality and the information it provides on embryonic development, contributes remarkably to the success of IVF.

 tl_files/images/2017/Capture d’ecran 2017-07-28 a 12.16.58.png

With the EmbryoScope +, microscopy evolves. This innovative laboratory tool integrates a camera within a new generation incubator. This makes it possible to obtain images of embryo development in vitro without disturbing them. The built-in camera is programmed to take pictures of each embryo at regular intervals (every 10 minutes). A time-lapse video covering the duration of the culture (3 to 6 days) is thus generated for each embryo. Embryologists can track the development of embryos continuously without extracting them from the incubator. In this way, extremely stable incubation conditions are maintained, fundamental for optimal development before in utero transfer. 

Time-lapse technology also provides additional information on the ability of embryos to develop (morphological and kinetic criteria). Embryologists can refine their analysis and thus identify, before their transfer, the embryo or embryos with the greatest chance of pregnancy.  Couples can visualize the development of their embryos and better understand the physiological processes from fertilization to transfer in utero.

tl_files/images/2017/Capture d’ecran 2017-07-28 a 12.21.17.png

August 2017

Recognition of Competences

We warmly congratulate our colleagues Dr. Antonella Biondo and Dr. Fabien Murisier, biologists at the CPMA Laboratory (Fertisupport), who passed the Senior Clinical Embryologist examination of the European Society of Human Reproduction and Embryology (ESHRE).

Fertisupport thus becomes the first Swiss laboratory to include five biologists with competencies recognized at the European level. Dr. Françoise Urner (PhD, ESHRE Senior Clinical Embryologist) is the Director of Fertisupport, whose team includes Dr. Antonella Biondo (PhD, ESHRE Senior Clinical Embryologist), Dr. Charlotte Coat (MD and MSc, ESHRE Senior Clinical Embryologist), Dr Fabien Murisier (PhD, ESHRE Senior clinical embryologist), and Ms Josefina Vargas (MSc, ESHRE clinical embryologist).

Honorary Member of ESHRE

On 2 July 2017, Dr. Marc Germond, founding physician of the CPMA, was awarded with an Honorary Membership of the European Society for Human Reproduction and Embryology (ESHRE), in view of his active participation and scientific contributions in the field of ​​medically assisted procreation.

The award was given at the opening ceremony of the annual ESHRE conference in Palexpo in Geneva. The picture below shows Dr. Germond in the center, surrounded by the ESHRE Presidents, Dr. Roy Farquharson and Dr. Kersti Lunden.

tl_files/images/2017/2017_MGD1.jpg

Dr. Marc Germond has an FMH (Swiss college of physicians) specialization in gynecology and obstetrics, with extensive training in reproductive medicine, gynecological endocrinology and operative gynecology. He completed his knowledge in the treatment of infertility in 1984, in the service of Prof. CD Matthews, at the Fertility Unit of the Queen Elisabeth Hospital in Woodville, Australia. In 1987, he created and headed the Sterility Unit in the Department of Gynecology and Obstetrics of the CHUV (Prof. H. Bossart and P. De Grandi), where he was appointed Associate Professor in 2002.

Member of the Ethics Commission of ESHRE, he took part in 1991 in setting up the first European recommendations on medical practice in reproductive medicine, published in "Focus on Reproduction". In 1992, he was a founding member of the Swiss Society of Reproductive Medicine (SGRM / SSMR) and of the Swiss registry collecting the national statistics of the medically assisted reproductive cycles FIVNAT. In 2001, Dr Germond organized, for the first time in Switzerland, the ESHRE European Congress, which took place in Lausanne.

Over the years, his research extended to several fields, in particular concerning clinical advances in reproductive medicine and endocrinology, the use of lasers in reproductive medicine, andrology, psychological issues of infertile couples, the ethical issues of medically assisted procreation (MAP) and the investment of parents with their children conceived with the MAP.

Dr. Germond has received several research grants from the Swiss National Fund for Scientific Research (FNRS) and other institutions and has contributed to the publication of more than 100 articles in scientific books and journals.

In the spring of 2016, Dr. Germond retired from the CPMA. However, he remains active in the Medisupport as Fertility Medical Advisor , and participates in the development of future strategies.

The CPMA is very pleased with this international recognition, at the highest level, of its founder and former Director, Dr. Marc Germond.

European Congress

The CPMA actively took part in the Annual Congress of the European Society of Human Reproduction and Embryology (ESHRE), which took place in Geneva from 2 to 5 July, 2017.  This is an annual international meeting that usually attracts more than 8'000 participants. 

Biologist Dr. Fabien Murisier PhD is a member of the Local Organizing Committee. He lectured on a new technology for pre-implantation diagnosis (PID). 

Gynecologist Dr. Dorothée Wunder PD MD was invited to talk about the general population's knowledge about fertility and the implications of fertility awareness. 

Dr. Marysa Emery MD  presented a clinical perspective on the limits of medically assisted procreation treatments. 

Gynecologists Dr. Daniel Wirthner MD and Dr. Dorothée Wunder PD MD, as well as biologists Dr. Françoise Urner PhD and Dr. Fabien Murisier PhD are invited to co-chair sessions of scientific presentations during the 4 days of the Congress. 

More information about the ESHRE Congress can be found at: ESHRE 2017

Discussion groups

Starting April 2017, the CPMA organises discussion groups for those who wish to share their experiences concerning fertility issues or treatment.

For more information or for inscriptions, please see below. The groups take place in French, hence the information is not translated:

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Les rencontres à thème du CPMA

Ouvert à tous, sur inscription

Vous souhaitez rencontrer d’autres couples ou personnes confrontés à une problématique autour de l'infertilité ou le projet d'enfant?

Nous vous proposons un groupe de rencontre afin d’échanger sur votre vécu, votre parcours et vos questionnements. 

Les professionnels de l’accompagnement psychologique du CPMA Lausanne, Dr Marysa Emery, médecin psychosomaticienne et Laure de Jonckheere, conseillère en santé sexuelle, vous accueilleront. Une brève introduction du thème sera faite, puis les participants pourront partager leurs expériences et questions.

Voici quelques exemples de thèmes: questions autour de l’infertilité féminine ou masculine, le vécu des traitements en PMA, la perte d’une grossesse, réflexions autour du deuil de la parentalité, l’enfant et l’histoire de sa conception…

Pour des questions d'organisation, les dates de rencontre seront proposées à partir de 6 inscriptions.

Vous pouvez vous inscrire à l'adresse email suivante: cpma@cpma.ch 

Merci d'indiquer votre nom, prénom et adresse email, en mentionnant votre intérêt pour participer à une Rencontre à Thème au CPMA Lausanne. Vous pourrez également nous faire part d'un thème qui vous tient à coeur. Votre inscription est confidentielle, votre nom ne sera pas communiqué aux autres participants. Nous vous rendrons réponse et vous enverrons la première date prévue dans les meilleurs délais.

Bienvenue à toutes et à tous!

 :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

 Le CPMA organise d’autres rencontres, sur inscription, pour les couples suivis par les médecins du réseau du CPMA. Les couples confrontés aux questions autour du don de sperme ou d’ovocyte ont la possibilité de participer à des réunions spécifiques. Des informations supplémentaires peuvent être obtenues à la réception du CPMA ou à l’adresse : cpma@cpma.ch

 CPMA SA, Rue de la Vigie 5, CH – 1003 Lausanne

Plus d’informations :  cpma@cpma.ch

 

The CPMA in the SwissTech Convention Center

From November 24th to 27th, 2016, the CPMA was present in the Swiss Health Salon (Salon Suisse de la Santé) in the SwissTech Convention Center on the EPFL Campus in Dorigny near Lausanne.

Meet the CPMA in the "Planète Santé" Salon to approach different subjects around the theme of fertility.

Three conferences are on the program for Sunday, November 27th, from 2 to 4 PM.

This is an event organised for the general public with various animations and conferences, for anyone interested in present health issues and challenges.

For more information:
http://www.planetesante.ch/salon

 

Recognition of competences

We warmly congratulate our colleague Dr. Charlotte Coat, working as a physician-biologist at Fertisupport, who has successfully passed the Senior Clinical Embryologist of the European Society of Human Reproduction and Embryology (ESHRE).

Fertisupport hereby becomes the first laboratory of reproductive biology in Switzerland to include six biologists with recognized competencies at the European level. Dr. Françoise Urner (PhD, ESHRE Senior Clinical Embryologist) is the Director of Fertisupport, whose team includes Dr Alain Chanson (PhD, ESHRE Senior Clinical Embryologist), Dr Charlotte Coat (MD and MSc, ESHRE Senior Clinical Embryologist) Fabien Murisier (PhD, ESHRE clinical embryologist), Dr. Antonella Biondo (PhD, ESHRE clinical embryologist  ), Dr. Josefina Vargas (MSc, ESHRE clinical embryologist).

August 2016

Le peuple suisse a dit OUI le 5 juin 2016

Le peuple suisse a dit OUI à la révision de la loi sur la procréation médicalement assistée…

Le 5 juin 2016, 62.4% des suisses ont voté OUI à  la révision de la loi concernant la procréation médicalement assistée. C’est dans le canton de Vaud que le taux d’acceptation a été le plus haut, avec 85% des voix en faveur du nouveau texte (www.admin.ch).

 Nous remercions toutes les personnes qui, par leur témoignage ou leur engagement, ont permis à cette loi d’être largement acceptée.

Grâce à cette nouvelle loi, les nouvelles dispositions qui pourront être mises en place nous permettront d’optimiser les traitements que nous proposons dans notre centre, et nous nous en réjouissons.

Parution du Livre "Voyage en Zygotie. Histoires d'embryons"

par Dominique Laufer et Véronique Mauron.

L'histoire des embryons de la procréation médicalement assistée parue aux éditions Cécile Defaut en janvier 2016 (http://www.encd.fr/fr/), traite des embryons congelés et de leur destin, et aborde de manière plus vaste les conséquences individuelles et sociétales de ces biotechnologies. Au travers des récits des couples interviewés, ce livre, préfacé par François Ansermet et Marc Germond, est moins une thèse qu'un aiguillon pour la pensée. Plutôt que d'apporter des réponses, il soulève des questions autour des origines, de la filiation et de la mort. Son originalité réside dans l'association d'une pédopsychiatre, Dominique Laufer , qui a travaillé plusieurs années au sein du CPMA, et d'une historienne de l'art, Véronique Mauron, auteur, avec François Ansermet, Marc Germond, Marie André et Francesca Cascino, du livre "Clinique de la procréation et mystère de l'incarnation: L'ombre du futur". 

Appointment to the National Ethics Committee

PD Dr. med. Dorothea Wunder has been appointed by the Federal Council to the National Commission of Ethics in the field of human medicine.

The aims of the Commission of the Federal Office of Public Health (BAG) is to " inform on the state of medical research and to evaluate the social impact and ethical issues of biotechnology in human medicine, whilst leading a global ethical reflection   ". It is composed of a Chairperson and 15 members with philosophical ethics skills that are selected and appointed by the Federal Council. You will find more information on the work of the Commission through the following link    

http://www.nek-cne.ch/fr/la-commission/apercu/

[Nbsp] The CPMA is pleased to announce the appointment of PD Dr. med. Wunder. Her active participation in the mission of the National Commission of Ethics reinforces and reflects the interest of our Center for these critical and current issues.

Successful recertification audits in the CPMA and Fertisupport

On 27 November 2015, the CPMA successfully passed the recertification audit using the new version 2015 ISO 9001. The lead auditor was Dre. Christine Stebler SQS (Swiss Association for Quality and Management Systems).

A few days later, on December 3, 2015, the laboratory of reproductive médecine Fertisupport of the CPMA in Lausanne, Fribourg (HFR) and Geneva (HUG) successfully passed the renewal of accreditation assessment, passing from ISO / IEC 17025 to ISO 15189: 2013. The leaders of the assessment were Mr. Ian Mann SAS (Swiss Accreditation Service) and the Magister Marc Van den Bergh, ESHRE senior clinical embryologist of Quartec. 

These renewals and changes of standards were controlled by the PD Dr. Alain Chanson, quality manager of the CPMA and Fertisupport. These procedures allow to insure the maintenance of optimal care for patients and rigor and competence in communicating with the doctors involved.

Reunion for specialists in medically assisted procreation

The reunion for medical and biologist specialists organized by the CPMA took place in Lausanne-Ouchy on November 5, 2015.

The program, in French, was as follows:

15h00 Accueil des participants

15h15 Introduction - Dr Daniel Wirthner et Dr Marc Germond

15h30 L’imagerie de l’utérus - Dr Nathalie Beurret

15h50 Isthmocèle : diagnostic et prise en charge - Dr Alexandre Megalo et Dr Eric Chardonnens

16h10 L’endomètre pathologique en PMA - Dr Daniel Wirthner

16h30 Pause

17h00 Cas clinique - Dr Rachel Cirafici

17h20 Comment éviter les grossesses multiples en FIV ? - Dr Charlotte Coat

17h50 Update sur la ménopause - PD Dr Dorothea Wunder

18h20 Conclusion

 

The next reunion will take place in 2016

 

Recognition of competence

July 2015

The professional competence of five Fertisupport biologists has been attested by the European Society of Human Reproduction and Embryology (ESHRE)

Dr Antonella Biondo (PhD) and Josefina Vargas (MSc) have successfully passed the examination for the title of "ESHRE clinical embryologist" at the last congress of the European Society of Human Reproduction and Embryology in Lisbon. They thereby join their colleagues, Dr Françoise Urner (PhD, senior clinical embryologist ESHRE), PD Dr. Alain Chanson (PhD, senior clinical embryologist ESHRE) and Dr Fabien Murisier (PhD, clinical embryologist ESHRE).

Fertisupport is the first laboratory of reproductive biology in Switzerland to have five biologists with recognized expertise at the European level and being able to provide patients with optimal care.

The eight Fertisupport biologists work in three laboratories of reproductive biology. The main laboratory is located in the CPMA in Lausanne, while two antennas operate in the Fribourg Cantonal Hospital (Dr. Anis Feki) and the Geneva University Hospital (Dr Isabelle Streuli).

The three Fertisupport sites are accredited by the Swiss Accreditation Service (SAS) according to ISO / IEC 17025. The competences of Fertisupport and of its biologists in the field of reproductive biology are thus officially recognized and guaranteed.

The CPMA grows and strengthens

April 2015

The CPMA grows and strengthens. Starting April 1st 2015, PD MD Dr Dorothea Wunder has joined the CPMA team. Our patients and team will benefit from her knowledge, skill and experience in gynecological endocrinology and in reproductive medicine.

Indeed, the PD Dr. Wunder took leave of the Reproductive Medicine Unit of the University Hospital of Lausanne (CHUV) which she headed until 03/31/2015 in order to join the CPMA where she was invited to complete the medical team.

 Dr. Dorothea Wunder received her medical degree, MD, in 1993 at the Basel School of Medicine. She specialized thereafter in obstetrics and gynecology in various hospitals such as Fribourg, Olten, Inselspital Bern and abroad (Capetown, New York and Gothenburg).

Her extensive training led to her specialization in reproductive medicine and gynecological endocrinology, obtained in 2001 in the Service of Prof.  Birkhäuser in the Inselspital Bern, where she became resident physician and replacement of the Chief resident in 2003.  In 2008 she worked as Head of the Reproductive Medicine Unit in the CHUV, as well as teaching and maintaining her research activity, with the double title of lecturer (PD) at the Universities of Bern and Lausanne.

In addition to the clinic, Dresse Wunder, who is fluently bilingual, is very active in her specialty’s medical societies (Swiss Society of Reproductive Medicine, Switzerland Menopause Society) as well as many national committees. She also chairs the Committee FertiSave (fertility preservation).

 

Swiss Health Exhibit

December 2014
 
The Swiss Health Exhibit was held from November 13 to 16, 2014 in the Swiss Tech Convention Center on the site of the EFPL (Ecole Fédérale Polytechnique de Lausanne) in Dorigny , Lausanne. The CPMA and Fertas put forth[ nbsp ] their medical, biological and analytical features, amongst many other health professionals . This is a show for the general public with conferences and events , for all people interested in the various current challenges of health care. For more information: http://www.planetesante.ch then click the " Show " tab.
 
 The next show is scheduled for November 2016

Preservation of female fertility

March 2014
 
The vitrification of oocytes (female gametes or "eggs") is a technique which allows to preserve the fertility of women who are in the need to postpone their parental project.
In recent years, new technical advances have led to improved methods of preserving female fertility. This possibility concerns patients subjected to sterilizing medical treatment, but also to young women who want to anticipate a potential decline in fertility. Since it is not possible to change the ovarian reserve, which can be extremely variable from one woman to another, some women will turn to the possibility of   keep their oocytes.
Oocyte vitrification is a way to "suspend time" by freezing oocytes that can be used later when the time comes to have a baby.
For more information and answers to frequently asked questions:   Conservation of female fertility

A reinforcement of our network for infertility care

October 2013

The CPMA - Lausanne and Fertas laboratory are pleased to announce their inclusion in the Network of Laboratories Medisupport . Focused on the needs of the patients, this synergy strengthens our center of excellence in the diagnosis and treatment of infertility.

Medically assisted procreation (MAP) is continually evolving. Initially focused on the treatment of infertility, this domain also participates today in the preservation of fertility, and in the near future, in diminishing therapeutic abortion.In this context, the development of a multidisciplinary network of medical and technical skills is essential. It is in this spirit that the CPMA SA [ nbsp ] and Fertas SA, two pioneering companies in the areas of MAP, have joined forces with the Network of Laboratories Medisupport . We believe that this synergy will strengthen the foundation of our commitment to patients and their physicians [ nbsp ] : through excellent, personalized and efficient services.

Children born after IVF/ICSI

October 2012

A recent scientific publication * in the American Journal "Circulation", raises questions on the possible effects of IVF/ICSI on the chiildren's  health. The CPMA supports and participates in research while seeking to convey, in a comprehensive manner, the impact on the persons concerned. 

In summary:

A group of healthy children who were conceived through in vitro fertilization (IVF) participated in a scientific study published recently in the journal "Circulation". This study revealed the presence of markers linked, in other situations, to the possibility of developing a cardiovascular disease. It is the first reported observation of this type, meaning that further studies are needed to confirm it. The detection of this possible subtle effect on the cardiovascular physiology of children conceived through IVF confirms the importance of continued engagement in the scientific study of the complexity and sensitivity of natural mechanisms surrounding procreation and pregnancy.

Are the four million children born after in vitro fertilization (IVF) different from those conceived in vivo?
Dr Marc Germond MD

A recent article in the American medical journal "Circulation" once again raises the question: is a child born after IVF potentially different from one conceived "naturally"? Peculiarities discussed for years by researchers from various disciplines, from genetics to social sciences, now have a new "crystallization point": the cardiovascular system. This study, intelligent and well conducted, found that healthy children born after IVF carry markers for a possible development of cardiovascular disease in their lifetime. These markers were previously observed in children born to women with diabetes, who presented a low birth weight or who experienced major stress in the period from conception to birth. The impact of this observation is not known. The first child born from IVF is now 33 years old and the frequency of cardiovascular diseases among IVF children does not seem to be different from non-IVF children.

The origin of these detected markers is not known. Researchers suggest changes in gene expression occurring in a time of great sensitivity of the latter (epigenetic phenomenon). The environment, diet, exposure to toxins, aging and other "disruptors" may be involved in this phenomenon inherent in everyone and responsible for our "evolution" without our genome itself undergoing change. Thomas Jenuwein, Director of the Max Planck Institute of Immunobiology and Epigenetics, Freiburg in Breisgau in Germany, elegantly illustrates this phenomenon as follows: "You could compare the difference between genetics and epigenetics as the difference between writing a book and reading it. Once the book is written, the text (genes or information stored as DNA) will be the same in all the copies distributed to the public. However, each reader of a given book will have a slightly different interpretation of the story, as it arouses personal feelings and projections throughout the chapters. In a comparable manner, epigenetics allow different readings of a fixed matrix (the book or genetic code), giving rise to various interpretations, depending on the conditions under which this template is examined. "

In fact, the "Circulation" article highlights the potential risks that we are all sustaining in our environment, in the broadest sense. The 20th century has overcome the greatest amount of sterilities by the development of IVF and intracytoplasmic injection of sperm (ICSI). The 21st century requires of us the responsibility to continue the research necessary for the optimization of treatments available to patients. Thousands of researchers, including the CPMA and the F.A.B.E.R. Foundation, participate in the development of therapeutic tools and their monitoring. The field of medically assisted procreation (MAP) is immensely vast, confirmed by the recently raised issue: as the "children of science" become adults, we all must realize that only applied research allows to optimize treatment and that "blind routine" has no place in reproductive medicine.

By analogy, let us quote Professor George Peters of the Medical Faculty of Lausanne University, who began his course of clinical pharmacology by stating that: "There is no drug that has a primary effect without also having one or more secondary effects". Similarly, medically assisted procreation exists to overcome infertility in the reality offered by our society, and in the environment in which it evolves. Children of MAP need medical care, just like all of us, without denying or exaggerating a possible cardiovascular risk, which is highly variable and linked to many other phenomena considered as natural or induced.

Thus, for practitioners of medically assisted procreation and the couples involved, the interest of this study is that it has detected a subtle effect on the cardiovascular physiology of children conceived through IVF. This confirms the importance of continuing our commitment to scientific studies addressing the complexity and sensitivity of the natural processes of procreation and pregnancy.

PS: The epigenetic phenomenon seems to be a possible cause of many diseases such as, among others, male subfertility (see: http://pnr50.fondation-faber.ch/). The study of epigenetics is a new science, like MAP was 30 years ago.

* Systemic and Pulmonary Vascular Dysfunction in Children Conceived by Assisted Reproductive Technologies. Urs Scherrer; Stefano F. Rimoldi; Emrush Rexhaj; Thomas Stuber; Hervé Duplain; Sophie Garcin; Stefano F. de Marchi; Pascal Nicod; Marc Germond; Yves Allemann; Claudio Sartori 
Editorial: Manipulating Nature: Might There be a Cardiovascular Price to Pay for the Miracle of Assisted Conception? David S. Celermajer

Symposium on preimplantation genetic diagnosis

On August 30, 2011, Pro Infirmis Vaud organized a symposium on the theme of preimplantation diagnosis. This conference was held at the Congress Centre and Exhibition Beaulieu in Lausanne, under the title:

Disability and diagnosis at the dawn of life: hope or drift? Perspectives on the preimplantation diagnosis.

More information is available on the websitewww.info-handicap.ch from the home page.

The relocation of the CPMA

The relocation of CPMA to its new offices at Rue de la Vigie 5, 1003 Lausanne was held in early September 2010.

The CPMA team is pleased to concentrate the team and skills in one place!

The module

An artistic representation of ART has been made in the form of a mobile unit that has been exposed in several places in Switzerland. Proposed by the art historians Marie André et Véronique Mauron, the module is an audiovisual installation based on medical images from the Centre of Medically Assisted Procreation, Lausanne (CPMA). The artistic design is from Pierre-Yves Borgeaud (filmmaker, videographer, Lausanne), the architectural design of Konstantin Tzonis (Lausanne) and the music composition by Don Li (Berne). The Foundation F.A.B.E.R pilots the project. The module was exposed to the Ethnographic Museum of Neuchâtel (MEN), at the Neue Frauenklinik Lucerne, at the Claude Verdan Foundation in Lausanne and at the Maternity of Geneva (HUG).

tl_files/images/module001.jpg

The issues raised by the images of ART are breathtaking and overwhelming. Despite the accuracy and thoroughness of life technology, it seems important to highlight a dimension not spectacular of the look at the origin of life, because even if we are able to see how a body is born biologically, the mystery of our came into the world is preserved. Indeed, the module puts into situation the images of ART emphasizing the values ​​linked to life: respect, modesty, the presence of a mystery.

The module features a scientific information in an artistic language, visual and sound contemporary. This in itself is a creation that brings together science and art. During the visit, everyone is invited to reweave the links between practices and sophisticated medical technologies and te anthropological understanding of procreation.

tl_files/images/module002.jpg

  • The module was launched on 1 November 2007 at the Ethnographic Museum of Neuchatel (MEN).
  • February 15 to May 4, 2008, it was presented at the Neue Frauenklinik Luzern, Luzerner Kantonsspital, Luzern.
  • May 22 to September 28, 2008, he was presented to the Fondation Claude Verdan, Rue du Bugnon 21, Lausanne 1005.
  • Since May 9, 2010 until August 17, 2010, he was presented to the University Hospitals of Geneva (HUG), Geneva.
  • It was also exposed at the Rolex Center Dorigny EPFL (Lausanne) on 17 November 2010 to January 16, 2011.

CPMA, Rue de la Vigie 5, 1003 Lausanne, tél: 021 321 15 80